Influenza-Activated RNAi Constructs via Cap-Snatching
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments and vaccines for influenza are limited in their effectiveness due to the segmented nature of the influenza virus genome, leading to rapid emergence of new antigenic subtypes and variants, and existing antiviral drugs face challenges with resistance and side effects.
Innovation Solution
Development of an expression vector with a polynucleotide coding sequence encoding a precursor RNAi construct that includes a 5′ methylguanosine cap leader and an RNAi sequence, which is activated by the viral Cap-Snatching mechanism to inhibit viral replication and modulate host immune responses, specifically targeting influenza and other Cap-Snatching viruses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If vaccines and antiviral drugs are used to treat influenza, then protection against matched strains is provided, but resistance develops and side effects occur
Solution Approach 1:
The patent converts the virus's own cap-snatching mechanism, which is harmful for viral replication, into a beneficial trigger for activating RNAi therapeutics. The viral cap-snatching activity that enables influenza replication is simultaneously used to activate the therapeutic RNAi construct, turning the virus's weapon against itself.
Solution Approach 2:
The therapeutic system is designed to be self-activating through the viral cap-snatching mechanism. Once the virus infects the cell and begins its replication process, it automatically triggers the activation of the RNAi construct without requiring external administration or intervention, making the therapy self-service and responsive only when needed.
2Reliability
If RNAi is activated continuously to inhibit viral replication, then viral replication is suppressed, but toxicity and off-target effects increase
Solution Approach 1:
The RNAi construct is pre-installed in the cell in an inactive state, with the RNAi sequence already present but masked by the 5' UTR. The cap-snatching mechanism serves as the trigger that removes this mask and activates the pre-positioned therapeutic agent, ensuring it acts only when the virus is present.
Solution Approach 2:
The system transitions from a static, inactive state to a dynamic, active state only when triggered by viral cap-snatching. The RNAi construct is flexible in its design, allowing it to be stored inactive and then activated on-demand, changing its functional state based on the presence of the virus rather than remaining constantly active.
3Adaptability or versatility
If broad-spectrum antiviral treatment is used to cover multiple influenza subtypes, then coverage is expanded, but specificity to target sequences is reduced
Solution Approach 1:
The patent designs the RNAi construct with a universal activation mechanism (cap-snatching) that works across all influenza viruses, while the specific RNAi sequence can be tailored to target different viral substrates. This allows one activation system to serve multiple specific functions against different influenza subtypes and even other cap-snatching viruses.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach provides a novel method for treating, preventing, and diagnosing influenza infections by activating RNAi only in the presence of Cap-Snatching viruses, reducing toxicity and off-target effects, and offering a self-limited therapeutic response that targets specific viral sequences, thereby enhancing treatment efficacy and safety.
Implementation Method 1
activated by the viral Cap-Snatching mechanism to inhibit viral replication
Data Source
AI summary
The presently disclosed subject matter provides a novel approach for the treatment, prevention, and diagnosis of Cap-Snatching virus infections, particularly all classes of human influenza, including pandemic influenza. The methods involve the use of constructs for RNA-interference (RNAi).